All In Biotech

Drug Trial Radar · NCT05128487

A Study of NDI 1150-101 in Patients With Solid Tumors

A Phase 1/2, Open-label Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of NDI-101150 Administered as Monotherapy or in Combination With Pembrolizumab in Patients With Solid Tumors

Last checked: Nov 19, 2026Latest source record: Nov 25, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

106

Planned (sponsor's estimate)

Start

Nov 5, 2021

Primary completion

Feb 2025

Study completion May 2025

Sponsor

Lead sponsor
Nimbus Saturn, Inc.Industry
Sponsor type
Industry
First posted
Nov 22, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is to determine the maximum tolerated dose (MTD) and the recommended Phase 2 dose (RP2D) and to investigate the safety, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of NDI-101150 given as monotherapy or in combination with pembrolizumab in adult patients with advanced solid tumors.

Conditions

  • Solid Tumor
  • Renal Cell Carcinoma (Kidney Cancer)
  • Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma
  • Non-Small Cell Lung Cancer

Interventions

  • NDI-101150Drug

    NDI-101150 capsules

  • PembrolizumabDrug

    Pembrolizumab IV infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1: Frequency of dose-limiting toxicities (DLTs)Time frame: Cycle 1 (28 days)
  2. Part 2: Objective response rate (ORR)Time frame: Up to approximately 34 months

Locations

19 sites in 1 country. Site status is shown where the registry gives one.

  • Honor Health Research Institute

    Scottsdale, Arizona

  • Yale Cancer Center

    New Haven, Connecticut

  • Georgetown University

    Washington D.C., District of Columbia

  • Ocala Oncology Center

    Ocala, Florida

  • Norton Cancer Institute

    Louisville, Kentucky

  • University of Maryland Greenebaum Comprehensive Cancer Center

    Baltimore, Maryland

  • Henry Ford Cancer

    Detroit, Michigan

  • HealthPartners Cancer Research Center

    Saint Paul, Minnesota

  • Washington University

    St Louis, Missouri

  • Hackensack University

    Hackensack, New Jersey

  • Columbia University Irving Medical Center

    New York, New York

  • Stephenson Cancer Center

    Oklahoma City, Oklahoma

  • Texas Oncology - Baylor Charles A. Sammons Cancer Center

    Dallas, Texas

  • Center for Oncology and Blood Disorders

    Houston, Texas

  • Oncology Consultants

    Houston, Texas

  • NEXT Oncology

    San Antonio, Texas

  • NEXT Oncology

    Fairfax, Virginia

  • Northwest Medical Specialties

    Tacoma, Washington

  • University of Wisconsin

    Madison, Wisconsin

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.